

### SARS-CoV-2 Sequencing Update **17 December 2021**



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

Science and Innovation

REPUBLIC OF SOUTH AFRICA

The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 17 December at 08h35



Data license: <a href="https://www.gisaid.org/registration/terms-of-use/">https://www.gisaid.org/registration/terms-of-use/</a>

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258 Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101

Case data is based on specimen collection date. Cases from <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-epidemiological-brief/</u> Test data from <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-testing-summary/</u>



#### 805 genomes deposited in the past week

Bar graphs represent genomes sequenced per epiweek, with lines representing cases by collection date (weeks 18 – 50)

Genomes and cases presented as provincial total (percentage of national total) for epiweeks 18 - 49

PTP: percentage testing positive in week 49 (5 Dec – 11 Dec); the arrow indicates direction of change since the previous week (28 Nov – 4 Dec)



### Number of South African genomes deposited on GISAID, by specimen collection week, 2020 and 2021 (N=25 625\*)



\*This represents the cleaned, de-duplicated dataset of unique sequences. This dataset will be used for all further figures.

### GISAID genomes vs total cases, 2020 and 2021 (N=25 625)



All provinces, apart from GP, KZN, NC and WC, have comparable percentage of overall cases and overall sequenced genomes. The majority of November sequencing data is from Gauteng.



### **Omicron sub-lineage spike mutation profiles**



**BA.2** Lacks 69-70del so not detected by S-Gene Target Failure







### **Omicron (BA.1) spike mutations compared to other VOC/VOIs**



- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
  - including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
  - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape



### **Mutational profile of Omicron sequences**

Frequency of Spike SNVs for Omicron (n = 7747)



#### Frequency of whole genome SNVs for Omicron (n = 7761)



Mutational profile of Omicron is largely shared amongst all sequences. Low mutation frequencies for N417N, N440K, G446S and N764K are most likely a result of poor coverage due to primer drop off.



Percentage

### **Omicron global prevalence**

Detection of Omicron Globally (countries = 88; n = 7761)



Omicron has been detected in 88 countries across the globe (detections based on GISAID).



#### Proportion and number of clades by epiweek in South Africa, 2021 (N= 19 190)



Delta dominated South Africa's third wave with >80% frequency in October, with C.1.2 detection remaining <4%. Omicron dominated November sequencing data and appears to dominate in December, but sequencing is ongoing to determine its prevalence.



#### Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in **October – December 2021** December (N=356) October (N=733) Delta (21I) (n=20, 3%) Delta (21A) (n=8, 1%) Beta (20H, V2) (n=64, 9%) Beta (20H, V2) (n=1, 0.28%) Delta (21J) Omicron (21L, BA.2) (n=15, 4%) (n=589, 80%) C.1.2 (20D) (n=28, 4%) Delta (21) (n=2, 1%) Omicron (21K, BA.1) (n=1, 0.14%) Omicron (21K, BA.1) unassigned (n=16, 2%) Other (n=7, 1%) **November** (N=1082) (n=338, 95%) Omicron (21L, BA.2)-Unassigned (n=35, 3%) Delta (21) (n=130, 12%) (n=1, 0.09%) Delta (211) (n=7, 1%) Delta (21A) (n=11, 1%) Beta (20H, V2) (n=4, 0.37%) C.1.2 (20D) (n=10, 1%) Omicron (20B, BA.3) (n=8, 1%) Total Omicron in Dec: 353 (99.2%) Total Delta in Oct: 596 (84.2%) Omicron (21K, BA.1) (n=872, 81%) Total Delta in Nov: 120 (13.7%) Total Omicron in Nov: 881 (81.4%) Delta (21) Omicron (21K, BA.1) Omicron (20B, BA.3) Beta (20H, V2) Delta (21A) Delta (21l) Kappa (21B) Eta (21D) Other unassigned Omicron (21L, BA.2) C.1.2 (20D) Alpha (201, V1)

The Delta variant dominated in October in South Africa with >80% frequency. Omicron was first detected in South Africa in October. Omicron dominated in November, comprising 81% (881/1082) of sequences, and appears to still dominate in December (99%, 353/356)



### Detection Rates: Beta, Delta, C.1.2 and Omicron

Detection rates of variants being monitored in South Africa



C.1.2 has been detected at ≤ 4% of sequences monthly. Beta prevalence increased slightly in October but has since remained at low levels in November and December. Omicron first detected in South Africa on October 24<sup>th</sup>, accounting for 0.1% (n=1/733) genomes in October. Omicron has been dominant since November.



### Eastern Cape Province, 2021, n =1754





### Free State Province, 2021, n = 1061





### Gauteng Province, 2021, n = 5224





### KwaZulu-Natal Province, 2021, n = 2472





### Limpopo Province, 2021, n = 1149





### Mpumalanga Province, 2021, n = 1107





### Northern Cape Province, 2021, n = 1252





### North West Province, 2021, n = 1198





### Western Cape Province, 2021, n =3887



NGS-SA Network for Genomic Surveillance in South Africa

### Summary

- Variant of Concern Omicron
  - South Africa:
    - Earliest detection ca: 24 October, Eastern Cape
    - Dominated November sequencing data at 81% of genomes (n=881/1082)
    - Detected in all provinces
  - Global:
    - Detected in 88 countries worldwide
    - Split into three lineages based on different mutational profiles: BA.1 (21K), BA.2 (21L), BA.3 (new, not yet assigned a separate clade)
- Delta variant dominated in all provinces until end October
  - Delta sub-lineages varied by province
- C.1.2 lineage detected in all provinces of South Africa with prevalence of <4% of genomes per month







supported by the European Union" NATIONAL HEALTH LABORATORY SERVICE

This project (RIA2020EF-

3030) is part of the

EDCTP2 programme

**X**X

ЕDСТР

#### **University of Stellenbosch** & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff** 

#### University of Cape Town, NHLS & Western Cape Government

5



NHLS-UCT

Carolyn Williamson

Nei-yuan Hsiao

Diana Hardie

Kruger Marais

Stephen Korsman

Ziyaad Valley-Omar

Department. Health REPUBLIC OF SOUTH ATRICA WCG-UCT Mary-Anne Davies Hannah Hussev Andrew Boulle

health

Masudah Paleker Theuns Jacobs Erna Morden



#### UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Bruna Galvão Arghavan Alisoltani (U. California)

ネオ centre infectioux EDCTP

Robert Wilkinson

Darren Martin Nicola Mulder Wendy Burgers Ntobeko Ntusi Rageema Joseph Sean Wasserman Linda Boloko

NHLS Greenpoint Annabel Enoch

W

Samrc

CAPE TOWN HVTN

cience & innovation

Alment: New and Innevation

Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division** 

**University of Pretoria** 

ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist)

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

#### Funders:

٩

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

#### University of KwaZulu-Natal & Africa **Health Research Institute**



**UKZN-Inkosi Albert Luthuli** 

**Central Hospital** 

Dr Kerusha Govender Dr Tshepiso Mosito

Dr Khanyi Msomi

Dr Pravi Moodley

Dr Aabida Khan

Dr Lili Gounder

Dr Kerri Francois

Dr Cherise Naicker

Dr Joedene Chetty

UNIVERSITY OF

INYUVESI YAKWAZULU-NATALI

Mr Malcolm Ellapen

Mr Kubendran Reddy

The COVID-19 Bench team

Dr Neli Ngcaba

Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San** 

KRISP at UKZN:

AHRI **AHRT**AFRICA RESEARCH INSTITUTE Alex Sigal Sandile Cele Willem Hanekom

#### National Institute for Communicable Diseases



**Centre for Respiratory Diseases & Meningitis** Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans

Nicole Wolter

Sibongile Walaza Mignon du Plessis Stefano Tempia Mvuyo Makhasi Cheryl Cohen



Sequencing Core Facility Annie Chan Constantinos Kurt Wibmer Morne du Plessis Stanford Kwenda Phillip Senzo Mtshali

Mushal Allam Florah Mnyameni







ENTERS







**Cathrine Scheepers** 

Thandeka Moyo

Frances Ayres

Zanele Molaudzi

Bronwen Lambson

**Tandile Hermanus** 

Prudence Kgagudi

**Brent Oosthuysen** 

Penny Moore

Lynn Morris

**NICD Groups** 

AFRICA CDC

Group

Mashudu Madzivhandila

NICD COVID-19 response team

NICD SARS-CoV-2 Sequencing

**Tandile Hermanus** 



Zamantungwa Khumalo















UNIVERSITY OF THE FREE STATE UNIVERSITEIT VAN DIE VRYSTAAT YUNIVESITHI Y FREISTA'

UFS

NHLS Division of Virology Sabeehah Vawda Felicity Burt Thokozani Mkhize **Diagnostic laboratory staff** 

University of the

**Free State** 

**Dominique Goedhals** 

Armand Bester

Martin Myaga





Key to Diagnostic Excellent

ΑΜΡΑΤΗ

LABORATORIES

PathCare

1

Vermaak

FIOCRUZ

#### NHLS Koeleka Mlisana Zinhle Makatini Eugene Elliot Florette K. Treurnicht Kathleen Subramoney Oluwakemi Laguda-Akingba Shareef Abrahams Greta Hoyland Gloria Selabe

Jeannette Wadula

Elias Bereda

**Hyrax Biosciences** Simon Travers

**Cape Town HVTN Laboratory** Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research Hugo Tempelman CJ Umunnakwe **Lancet** Allison J. Glass Raquel Viana

Ampath Terry Marshall Cindy van Deventer Eddie Silberbauer

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

**Cytespace Africa Laboratories** Christa Viljoen

ARC-OVI Lia Rotherham **CAPRISA** Salim Abdool Karim Nigel Garret

**Additional support and collaborators** 

**UKZN - Big Data** Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara Africa CDC John Nkengasong Sofonias Tessema

Netcare: Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

#### DSI

Glaudina Loots

**SA MRC** Glenda Gray

















Africa Hugo Te Laboratories CJ Umu

#### UKZN-Inkosi Albert Luthuli Central Hospital



UNIVERSITY OF KWAZULU-NATAL INYUVESI YAKWAZULU-NATALI

Dr Khanyi Msomi Dr Kerusha Govender Dr Pravi Moodley Dr Aabida Khan Dr Lili Gounder Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty Dr Neli Ngcaba Dr Tshepiso Mosito Mr Malcolm Ellapen Mr Kubendran Reddy The COVID-19 Bench team

#### University of KwaZulu-Natal & Africa Health Research Institute



KRISP at UKZN: Tulio de Oliveira Richard Lessels Houriiyah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillay Emmanuel James San



#### 

Alex Sigal Sandile Cele Willem Hanekom

#### University of Stellenbosch & NHLS Tygerberg Virology



UNIVERSITEIT

NATIONAL HEALTH

Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga Bronwyn Kleinhans Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen Diagnostic laboratory staff



#### University of Cape Town, NHLS & Western Cape Government





NHLS-UCT Carolyn Williamson Nei-yuan Hsiao Diana Hardie Kruger Marais Stephen Korsman Ziyaad Valley-Omar WCG-UCT Mary-Anne Davies Hannah Hussey Andrew Boulle Masudah Paleker Theuns Jacobs Erna Morden

wellcome

centre infectious diseases research in africa





Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Bruna Galvão Arghavan Alisoltani (U. California) Robert Wilkinson Darren Martin Nicola Mulder Wendy Burgers Ntobeko Ntusi Rageema Joseph Sean Wasserman

Linda Boloko



ЕDСТР

velicome

**NHLS Greenpoint** 

Annabel Enoch



#### University of the Free State



UFS

Dominique Goedhals Armand Bester Martin Myaga Peter Mwangi Emmanuel Ogunbayo Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed



NHLS Division of Virology Sabeehah Vawda Felicity Burt

Thokozani Mkhize Diagnostic laboratory staff



#### National Institute for Communicable Diseases

#### NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service

#### **Centre for Respiratory Diseases & Meningitis** Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter Sibongile Walaza Mignon du Plessis Stefano Tempia Mvuyo Makhasi **Cheryl Cohen**

**Centre for HIV and STIs Jinal Bhiman Cathrine Scheepers Constantinos Kurt Wibmer** Thandeka Moyo Tandile Hermanus **Frances Ayres** Zanele Molaudzi **Bronwen Lambson Tandile Hermanus** Mashudu Madzivhandila Prudence Kgagudi **Brent Oosthuysen** Penny Moore Lynn Morris

#### **NICD Groups**

NICD COVID-19 response team NICD SARS-CoV-2 Sequencing Group



#### AFRICA CDC Centres for Disease Control and Prevention Safeguarding Africa's Health

Sequencing Core Facility Zamantungwa Khumalo Annie Chan Morne du Plessis Stanford Kwenda Phillip Senzo Mtshali Mushal Allam Florah Mnyameni Arshad Ismail









velicome

#### Zoonotic arbo and respiratory virus program Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria



#### ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist)

### NATIONAL HEALTH

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

#### Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz



## South African genomes submitted per submitting lab, 2020 and 2021 (N=25 625)



\*NGS-SA Labs
CERI: Centre for Epidemic Response and Innovation
KRISP: KZN Research Innovation and Sequencing Platform
NICD: National Institute for
Communicable Diseases
NHLS: National Health Laboratory
Service
SU: Stellenbosch University
UCT: University of Cape Town
UFS: University of the Free State
UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



### Variants of Concern (VOC)

WHO label	Pango lineage∙	GISAID clade	Nextstrain clade	Additional amino acid changes monitored°	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	+S:484K +S:452R	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H (V2)	+S:L18F	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J (V3)	+S:681H	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2	G/478K.V1	21A	+S:417N +S:E484K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
Omicron*	B.1.1.529	GRA	21K, 21L	+S:R346K	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 17 December 2021

•Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

\* See TAG-VE statement issued on 26 November 2021

• Only found in a subset of sequences

### **Currently designated Variants of Interest (VOI)**

WHO label	Pango lineage*	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Lambda	C.37	GR/452Q.V1	21G	Peru, Dec-2020	14-Jun-2021
Mu	B.1.631	GH	21H	Colombia, Jan-2021	30-Aug-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 17 December 2021

<sup>\*</sup>Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

### Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
  - all ages
  - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
  - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
  - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

# Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)